Stockreport
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
Last cti biopharma corp earnings: 11/1 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations: ctibiopharma.com
PDF
SEATTLE, Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI BioPharma is eligible to receive up to an additional $40 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.About CTI BioPharma Corp.CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. The CTI BioPharma lead product candidate, pacritinib, is be
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CTIC | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CTIC alerts
CTIC alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTIC alerts
High impacting CTI BioPharma Corp news events
Weekly update
A roundup of the hottest topics
CTIC
NEWS
NEWS
- CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27[PR Newswire]
- CTI Bio down 8% premarket on withdrawal of pacritinib application in Europe [Seeking Alpha][Seeking Alpha]
- CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update[PR Newswire]
- CTI BioPharma: Can It Differentiate Itself From Jakafi In MF Patients? [Seeking Alpha][Seeking Alpha]
- CTI BioPharma Corp (NASDAQ: CTIC) was given a new $4.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a "buy" rating on the stock.[MarketBeat]
- More
CTIC
SEC Filings
SEC Filings
- 2/13/19 - Form SC
- 2/11/19 - Form 8-K
- 2/1/19 - Form 8-K
- CTIC's page on the SEC website
- More